Earlier this week, bigger rival Pfizer Inc mentioned it expects $26 billion in gross sales of its Covid-19 vaccine this yr.
Moderna had in February forecast vaccine gross sales of $18.4 billion.
Since then, rich nations have been stocking up photographs from Moderna and Pfizer Inc/BioNTech SE after security issues and manufacturing issues briefly sidelined AstraZeneca Plc and Johnson & Johnson vaccines.
Within the first quarter ended March 31, Moderna’s vaccine introduced in gross sales of $1.7 billion.
The corporate mentioned it plans to file for full approval of the vaccine in the US this month.